Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Impact of sevelamer versus calcium-based binders on hospitalizations and missed in-center dialysis treatments among CKD patients on dialysis: a modeled analysis.

Grima DT, Dunn ES, Bernard LM, Mendelssohn DC.

Curr Med Res Opin. 2013 Feb;29(2):109-15. doi: 10.1185/03007995.2012.756808.

PMID:
23216385
2.

A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.

Bernard L, Mendelssohn D, Dunn E, Hutchison C, Grima DT.

J Med Econ. 2013;16(1):1-9. doi: 10.3111/13696998.2012.718019.

PMID:
22857538
4.

Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.

Patel L, Bernard LM, Elder GJ.

Clin J Am Soc Nephrol. 2016 Feb 5;11(2):232-44. doi: 10.2215/CJN.06800615. Review.

5.
6.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Review.

PMID:
19692157
7.
8.

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.

Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.

Clin Ther. 2012 Jul;34(7):1531-43. doi: 10.1016/j.clinthera.2012.06.006.

PMID:
22742885
9.

Economic evaluation of sevelamer in patients with end-stage renal disease.

Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M.

Nephrol Dial Transplant. 2007 Oct;22(10):2867-78.

PMID:
17595182
10.

The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.

Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE; Collaborative Study Group..

Am J Kidney Dis. 2015 Sep;66(3):479-88. doi: 10.1053/j.ajkd.2015.03.013.

11.
12.

Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.

Thompson M, Bartko-Winters S, Bernard L, Fenton A, Hutchison C, Di Iorio B.

J Med Econ. 2013;16(6):744-55. doi: 10.3111/13696998.2013.792267.

PMID:
23550810
13.

A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.

Prajapati VA, Galani VJ, Shah PR.

Saudi J Kidney Dis Transpl. 2014 May;25(3):530-8.

14.

Comparative effectiveness of calcium acetate and sevelamer on clinical outcomes in elderly hemodialysis patients enrolled in Medicare part D.

Yusuf AA, Weinhandl ED, St Peter WL.

Am J Kidney Dis. 2014 Jul;64(1):95-103. doi: 10.1053/j.ajkd.2013.11.015.

15.

The effect of sevelamer hydrochloride and calcium-based phosphate binders on mortality in hemodialysis patients: a need for more research.

Assimon MM, Mousa S, Shaker O, Pai AB.

Consult Pharm. 2010 Jan;25(1):41-54. doi: 10.4140/TCP.n.2010.41. Review.

PMID:
20211816
16.

Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.

Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A, Kelly A, Chasan-Taber S, Duggal A, Fan S.

Nephrol Dial Transplant. 2009 Jan;24(1):278-85. doi: 10.1093/ndt/gfn488.

PMID:
18820280
17.

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

Goldsmith DR, Scott LJ, Cvetković RS, Plosker GL.

Drugs. 2008;68(1):85-104. Review.

PMID:
18081374
18.

Economic Evaluation of Sevelamer versus Calcium-based Binders in Treating Hyperphosphatemia among Patients with End-stage Renal Disease in China.

Yang L, Chuen Tan S, Chen C, Wang X, Li X, Yang X.

Clin Ther. 2016 Nov;38(11):2459-2467.e1. doi: 10.1016/j.clinthera.2016.09.012.

PMID:
27751671
19.

Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.

Park H, Rascati KL, Keith MS, Hodgkins P, Smyth M, Goldsmith D, Akehurst R.

Value Health. 2011 Dec;14(8):1002-9. doi: 10.1016/j.jval.2011.05.043.

20.

Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.

St Peter WL, Liu J, Weinhandl ED, Fan Q.

Hemodial Int. 2008 Oct;12(4):480-91. doi: 10.1111/j.1542-4758.2008.00312.x.

PMID:
19090871

Supplemental Content

Support Center